MRSN — Mersana Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
Mersana Therapeutics Inc (MRSN) is a biotechnology company listed on NASDAQ. It is led by Martin H. Huber M.D., based in 840 Memorial Drive, Cambridge, MA, United States, 02139, with about 102 employees. Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana Biosciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts. As of January 6, 2026, Mersana Therapeutics, Inc. operates as a subsidiary of Day One Biopharmaceuticals, Inc.
Latest reported MRSN revenue for 2025-09-30 was $11.0M. Net income was -$56.0M. Revenue was up 260.2% from 2025-06-30 to 2025-09-30. MRSN currently screens at market cap $145.4M.
Use this MRSN page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the MRSN quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the MRSN SEC filings page. Lician reads the product cache first so this HTML stays unique to Mersana Therapeutics Inc even when a live quote feed is slow.
About Mersana Therapeutics Inc
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana Biosciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts. As of January 6, 2026, Mersana Therapeutics, Inc. operates as a subsidiary of Day One Biopharmaceuticals, Inc.
MRSN Key Statistics
Market Cap
$145.36M
P/B Ratio
32.03
EPS
-$0.56
Revenue
$40.50M
Net Income
-$69.19M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+9.9%
Profit Margin
-170.9%
Employees
102
MRSN Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $40.50M | $36.85M | $26.58M | $43.00K |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$69.19M | -$171.67M | -$204.21M | -$170.06M |
| EPS (Diluted) | -$0.56 | -$1.48 | -$2.18 | -$2.41 |
Total Assets
$144.66M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$107.75M
Operating Cash Flow
-$82.34M
Free Cash Flow
$0.00
Mersana Therapeutics Inc Company Information
- President, CEO & Director
- Martin H. Huber M.D.
- Headquarters
- 840 Memorial Drive, Cambridge, MA, United States, 02139
- Website
- www.mersana.com
- Phone
- 617 498 0020
- IPO / Founded
- 2017-06-28
- Sector
- Healthcare
- Industry
- Biotechnology